Novartis Ag (NVSEF) Receivables - Other (2017 - 2025)

Novartis Ag has disclosed Receivables - Other across 9 years of filings, most recently posting $1.1 billion for Q4 2025.

• Receivables - Other for Q4 2025 came in at $1.1 billion, up 4.01% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.1 billion (up 4.01% YoY), and the FY2025 annual result was $1.1 billion, up 4.01% from the prior year.
• Receivables - Other came in at $1.1 billion for Q4 2025 at Novartis Ag, up from $1.1 billion in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.3 billion in Q4 2023 to a low of $793.0 million in Q4 2021.
• The 5-year median for Receivables - Other is $1.1 billion (2024), against an average of $1.0 billion.
• Across the five-year window, Receivables - Other slipped 17.65% in 2021 and soared 30.69% in 2023, its largest moves.
• Novartis Ag's Receivables - Other stood at $793.0 million in 2021, then increased by 20.81% to $958.0 million in 2022, then jumped by 30.69% to $1.3 billion in 2023, then dropped by 12.38% to $1.1 billion in 2024, then gained by 4.01% to $1.1 billion in 2025.
• The last three Receivables - Other figures came in at $1.1 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.3 billion (Q4 2023), per Business Quant data.